AbbVie to present an overview of its innovative pipeline reinforcing Its Tactics of delivering new therapies

AbbVie

, a global biopharmaceutical company, indicated that it would present an overview of its innovative pipeline reinforcing its tactics of delivering new therapies at am R&D Day meeting for the investment community. According to the company, it would significantly advance and reset the standard of care. AbbVie said that several current therapies in oncology, immunology, virology, neuroscience and women's health were not sufficient enough in meeting the medical needs of patients. Aside from that, several of the diseases in these therapeutic areas were debilitating, life-threatening and cause a significant burden on healthcare systems throughout the world. The company's chairman and CEO, Richard Gonzalez, commented, "Since becoming an independent company in 2013, AbbVie has developed a robust and diversified pipeline focused on diseases that have compelling medical needs. AbbVie's R&D pipeline of more than 50 active clinical development programs has AbbVie poised to deliver a consistent stream of innovative new medicines for patients while driving long-term growth through 2020 and beyond." Similarly, its EVP R&D and CSCO, Michael Severino, added, "AbbVie's late-stage pipeline has the potential to deliver more than 20 new medicines or indications by 2020, with the approval of seven new medicines or indications expected in 2016. These new medicines, combined with our early-stage clinical programs, have the potential to address medical need, elevate the standard of care and improve patient outcomes." AbbVie stated that its early-stage pipeline leveraged its investments in early discovery, genomics, novel biology and enabling technologies that drive its focus on identifying new therapies that could reset the standard of care in oncology, immunology and neuroscience. The company's goal with these programs was to drive deep and durable disease control that enhances patients' outcomes and significantly reduces the burden on the healthcare system. On Friday, the stock traded 0.58 percent down.